![IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia](https://www.mdpi.com/ijms/ijms-22-02150/article_deploy/html/images/ijms-22-02150-g001.png)
IJMS | Free Full-Text | A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
![A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas](https://www.jhoponline.com/images/jhop/2022/February/Review_CAR_T-Cell_figure1.jpg)
A Review of CAR T-Cell Therapies Approved for the Treatment of Relapsed and Refractory B-Cell Lymphomas
![Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs40364-020-00197-1/MediaObjects/40364_2020_197_Fig4_HTML.png)
Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies | Biomarker Research | Full Text
![CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F2162-3619-1-36/MediaObjects/40164_2012_Article_34_Fig1_HTML.jpg)
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology & Oncology | Full Text
![Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology](https://pubs.acs.org/cms/10.1021/acssynbio.1c00010/asset/images/large/sb1c00010_0004.jpeg)
Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients | ACS Synthetic Biology
![JCI Insight - A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases JCI Insight - A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases](https://df6sxcketz7bb.cloudfront.net/manuscripts/166000/166137/medium/jci.insight.166137.ga.jpg)
JCI Insight - A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases
of CD19 and CD20 expression during B cell development. CD19 expression... | Download Scientific Diagram
![B cell depletion therapies in autoimmune disease: advances and mechanistic insights | Nature Reviews Drug Discovery B cell depletion therapies in autoimmune disease: advances and mechanistic insights | Nature Reviews Drug Discovery](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41573-020-00092-2/MediaObjects/41573_2020_92_Fig1_HTML.png)
B cell depletion therapies in autoimmune disease: advances and mechanistic insights | Nature Reviews Drug Discovery
![Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL](https://www.frontiersin.org/files/Articles/1165870/fimmu-14-1165870-HTML/image_m/fimmu-14-1165870-g001.jpg)
Frontiers | Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
![Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor: Molecular Therapy - Oncolytics Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor: Molecular Therapy - Oncolytics](https://www.cell.com/cms/asset/b90b2fa9-07b6-4619-980c-a83657596e6c/fx1.jpg)
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor: Molecular Therapy - Oncolytics
![CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia - Weiland - 2015 - Pediatric Blood & Cancer - Wiley Online Library CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia - Weiland - 2015 - Pediatric Blood & Cancer - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7c59a537-2ce7-4542-853c-6a98367b209d/pbc25462-fig-0001-m.jpg)